Long-Term Tolerability and Safety of AAV5 -Id3 Gene Therapy to Eyes
Translational Vision Science & Technology · 2026
DOI: 10.1167/tvst.15.1.38 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2026. Verfasst von Suneel Gupta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Cornea, Corneal Diseases. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NEI NIH HHS.
Abstract (Originalsprache)
Purpose
The inhibitor of differentiation 3 gene therapy via adeno-associated virus 5 (AAV5-Id3) effectively abrogated corneal fibrosis in vivo. This study examined the long-term tolerability and safety of AAV5-Id3 gene therapy for eyes in vivo using a rabbit model.
Methods
Eighteen New Zealand White rabbits, segregated into three groups (naive, AAV5-naked, and AAV5-Id3; n = 6/group), were used. The clinical eye examinations with slit-lamp and multimodal corneal imaging were performed in live rabbits periodically to record the status of ocular and corneal health for up to 7 months. Thereafter, humane euthanasia was performed, and cellular and molecular changes in corneas were studied employing histopathologic, immunofluorescence, and quantitative reverse transcription polymerase chain reaction (RT-PCR) techniques.
Results
Periodic masked eye examinations with slit-lamp, Spectralis, HRT3-RCM, and specular ophthalmic microscopes found no significant differences in the corneas of naive, AAV5-naked, and AAV5-Id3 groups. Modified McDonald-Shadduck scores revealed no signs of blepharospasm, chemosis, abnormal discharge, epiphora, erythema, or epithelial abrasion in three groups. Pachymetry, tonometry, and fluorescein testing detected no alterations in corneal thickness, intraocular pressure, and tear volume in eyes of the three groups. Histopathologic studies revealed corneal architecture, cellular organization, cellular morphology, and collagen levels similar in eyes of the three groups. Quantitative RT-PCR analysis did not find changes in nuclear factor κB, tumor necrosis factor α, α-smooth muscle actin, fibronectin, vascular endothelial growth factor, and pigment epithelium-derived factor messenger RNA levels in three test groups. At 7 months, AAV5-Id3 corneas had 2.73 × 102 ± 0.34 delivered-Id3 gene copies.
Conclusions
Targeted topical AAV5-Id3 gene therapy is tolerable, safe, and nontoxic to the eyes in vivo. Translational Relevance: Topical AAV5-Id3 gene therapy treats corneal fibrosis without significant side effects in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA.
- Department of Veterinary Medicine & Surgery and Pathobiology and Integrative Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA.
- Mason Eye Institute, School of Medicine, University of Missouri, Columbia, MO, USA.
Förderung
- BLRD VA
- NEI NIH HHS
Zitieren
APA
Gupta, S., Kumar, R., Sinha, N. R., Martin, L. M., Sinha, P. R., Fraunfelder, F. W., Hofmann, A. C., Hesemann, N. P., & Mohan, R. R. (2026). Long-Term Tolerability and Safety of AAV5 -Id3 Gene Therapy to Eyes. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.15.1.38
Vancouver
Gupta S, Kumar R, Sinha NR, Martin LM, Sinha PR, Fraunfelder FW, et al. Long-Term Tolerability and Safety of AAV5 -Id3 Gene Therapy to Eyes. Translational Vision Science & Technology. 2026. doi:10.1167/tvst.15.1.38
BibTeX
@article{Gupta2026,
author = {Gupta, Suneel and Kumar, Rajnish and Sinha, Nishant R and Martin, Lynn M and Sinha, Prashant R and Fraunfelder, Frederick W and Hofmann, Alexandria C and Hesemann, Nathan P and Mohan, Rajiv R},
title = {Long-Term Tolerability and Safety of AAV5 -Id3 Gene Therapy to Eyes},
journal = {Translational Vision Science & Technology},
year = {2026},
doi = {10.1167/tvst.15.1.38}
}
EUVIMED